Takeda Pharmaceutical (NYSE:TAK) Posts Earnings Results, Beats Estimates By $0.31 EPS

Takeda Pharmaceutical (NYSE:TAK) posted its earnings results on Thursday. The company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.31, Zacks reports. The business had revenue of $7.50 billion for the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. Takeda Pharmaceutical updated its FY 2026 guidance to 3.009-3.009 EPS.

Here are the key takeaways from Takeda Pharmaceutical’s conference call:

• Q1 results were broadly on plan: Core revenue declined 0.5% and core operating profit fell 0.5% at constant exchange rates, while core EPS decreased 11.8% to JPY 154 due largely to an unfavorable comparison with the prior year’s tax benefit. Full-year guidance, including JPY 650–750 billion of free cash flow, was maintained.
• The company reported continued resilience in its established portfolio, with core inline brands growing 2.3% at constant exchange rates. ENTYVIO grew 4%, new launches increased 22.6%, and transformation savings are intended to fund investments in upcoming products and the late-stage pipeline.
• Takeda is preparing for a potentially significant launch cycle, with ORZEYFUL for narcolepsy type 1 and rusfertide for polycythemia vera expected to launch in the U.S. in the second half of 2026, followed by zasocitinib for psoriasis in the first half of 2027. ORZEYFUL has already received its first approval in China, while rusfertide has received FDA priority review.
• Zasocitinib produced encouraging phase III psoriasis results, demonstrating statistical superiority to deucravacitinib across primary and key secondary endpoints, with more than 35% of patients achieving complete skin clearance at week 16. Management also highlighted promising data in difficult-to-treat areas and additional development opportunities in inflammatory bowel disease and other immune-mediated conditions.
• Near-term financial performance remains pressured by mature-product erosion, including continued generic competition for Vyvanse, while operating cash flow was lower because of working-capital effects and free cash flow included a $200 million payment to Protagonist related to rusfertide rights. ENTYVIO biosimilar litigation is expected to take roughly three to five years, with U.S. entry timing still broadly anticipated around 2032.

Takeda Pharmaceutical Price Performance

TAK traded down $0.15 during trading on Friday, hitting $17.09. The company’s stock had a trading volume of 3,219,089 shares, compared to its average volume of 3,139,228. The company has a quick ratio of 0.60, a current ratio of 1.09 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $54.77 billion, a price-to-earnings ratio of 43.83 and a beta of -0.07. The firm’s 50 day moving average price is $16.25 and its two-hundred day moving average price is $17.07. Takeda Pharmaceutical has a 12 month low of $12.99 and a 12 month high of $18.90.

Wall Street Analyst Weigh In

TAK has been the topic of several analyst reports. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Hold”.

Key Headlines Impacting Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Takeda reported fiscal first-quarter adjusted earnings of $0.48 per share, well above the $0.17 analyst consensus, while revenue rose to $7.50 billion versus expectations of $7.13 billion. The results reflect resilient performance from the company’s core portfolio. Takeda Pharmaceutical Fiscal Q1 Core Earnings, Revenue Rise
• Positive Sentiment: Takeda issued fiscal 2026 guidance for approximately $29.6 billion in revenue and $3.009 in EPS, above analyst expectations of roughly $29.0 billion and $1.57, respectively. The outlook supports the investment case, although the unusually precise EPS figure may reflect a reporting or formatting issue. Takeda Fiscal 2026 Guidance
• Positive Sentiment: Bank of America Securities analyst Koichi Mamegano reiterated a Buy rating and maintained his price target, citing the first-quarter beat and continued progress across Takeda’s development pipeline. Bank of America Reiterates Buy Rating
• Neutral Sentiment: Takeda will pay Keros Therapeutics a $20 million development milestone under their collaboration, signaling advancement of the partnered program but also representing near-term development spending. Keros Therapeutics Milestone Payment
• Neutral Sentiment: A UK Patents Court ruling imposed an extended prosecution bar in litigation involving Fresenius Kabi and Millennium Pharmaceuticals, a Takeda subsidiary. The immediate financial impact on Takeda is unclear. Patents Court Ruling
• Negative Sentiment: Takeda discontinued another Phase 2 therapy for celiac disease, leaving only one candidate in that area. The decision narrows the pipeline and increases reliance on the remaining program, weighing on longer-term growth expectations. Takeda Celiac Disease Program Discontinued

Institutional Trading of Takeda Pharmaceutical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Franklin Resources Inc. boosted its position in shares of Takeda Pharmaceutical by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after acquiring an additional 713 shares in the last quarter. Lido Advisors LLC raised its position in Takeda Pharmaceutical by 4.4% during the third quarter. Lido Advisors LLC now owns 27,714 shares of the company’s stock valued at $406,000 after purchasing an additional 1,166 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Takeda Pharmaceutical by 56.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares in the last quarter. Parkside Financial Bank & Trust lifted its stake in Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after purchasing an additional 1,684 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC lifted its stake in Takeda Pharmaceutical by 14.0% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 17,584 shares of the company’s stock worth $274,000 after purchasing an additional 2,153 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.